Ribocure, a Suzhou Ribo Life Science Subsidiary, Reports 92% FXI Activity Reduction in Phase IIa Vortosiran Trial for Coronary Artery Disease

July 26, 2026

Clinical Trials Arena UK

Overview

Ribocure Pharmaceuticals, a subsidiary of Suzhou Ribo Life Science, announced promising initial results from its Phase IIa clinical trial of vortosiran (RBD4059), an siRNA therapy for coronary artery disease patients. The high-dose cohort demonstrated an impressive average 92% reduction in Factor XI (FXI) activity. No treatment-related serious adverse events were reported, and the data suggest the feasibility of infrequent dosing every 3-6 months, highlighting siRNA’s significant potential for reducing thrombotic risk in CAD.

In Depth

Key Findings

Ribocure Pharmaceuticals, a subsidiary of Suzhou Ribo Life Science, has announced groundbreaking initial results from its Phase IIa clinical trial of vortosiran (RBD4059), an siRNA therapy targeting coronary artery disease (CAD) patients. The study revealed an impressive average 92% reduction in Factor XI (FXI) activity in the high-dose cohort. This robust data suggests vortosiran’s strong potential to significantly reduce the risk of thrombotic events in CAD patients, further supported by a favorable safety profile with no reported treatment-related serious adverse events.

Technical and Clinical Details

Vortosiran is an siRNA (small interfering RNA) designed to specifically target and silence FXI. Factor XI is a crucial protein in the intrinsic pathway of the blood coagulation cascade, and its inhibition is hypothesized to reduce thrombotic risk while minimizing the bleeding complications often associated with conventional anticoagulants. Selective inhibition of FXI represents a novel approach to antithrombotic therapy, aiming to achieve a better balance between efficacy and safety.

The Phase IIa clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of vortosiran on FXI activity in CAD patients. The initial results demonstrated a dramatic average reduction of 92% in FXI activity in the high-dose group. This robust and sustained silencing capacity of FXI indicates the potential for a potent antithrombotic effect. Importantly, this therapeutic effect was achieved with an infrequent dosing schedule, suggesting administration every 3-6 months, which could significantly enhance patient adherence to therapy.

Throughout the trial, no treatment-related serious adverse events were reported, underscoring the favorable safety profile of vortosiran. The combination of high-efficiency FXI knockdown and a strong safety profile strongly positions vortosiran as a potential next-generation therapeutic for coronary artery disease and other thromboembolic conditions.

Background and Industry Context

Coronary artery disease remains a leading cause of mortality worldwide, with patients facing a high risk of thromboembolic events such as myocardial infarction and stroke. While existing anticoagulant therapies are effective, they are frequently associated with a heightened risk of serious bleeding complications, including gastrointestinal and intracranial hemorrhages. Consequently, there has been a long-standing need for novel anticoagulants that can reduce thrombotic risk with a lower propensity for bleeding.

FXI has emerged as a highly attractive target in the pharmaceutical industry due to its potential to prevent thrombotic events while simultaneously reducing bleeding risk through selective inhibition. siRNA technology, with its ability to precisely and specifically suppress gene expression, is an ideal platform for achieving such a selective pharmacological action.

Strategic Significance and Outlook

The excellent Phase IIa results for vortosiran have the potential to significantly alter the treatment landscape for coronary artery disease. Larger, longer-term clinical trials will be essential to confirm its sustained efficacy and safety in a broader patient cohort. If successful, vortosiran could become a new standard of care, either replacing or complementing existing anticoagulants. This success is also likely to accelerate the development of other siRNA-based therapies for various cardiovascular and thromboembolic disorders. Ribocure Pharmaceuticals, through this technology, is poised to bring transformative innovation to the high unmet medical need in the cardiovascular space.

Source: https://www.clinicaltrialsarena.com/news/ribo-vortosiran-phase-iia-trial-results/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.